Drug-related problems, adherence and quality of life in outpatients receiving endocrine treatment for hormone receptor-positive breast cancer: A prospective study
Journal of Oncology Pharmacy Practice, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1177/10781552261494092
- Dergi Adı: Journal of Oncology Pharmacy Practice
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: breast cancer, Clinical pharmacy, drug-related problems, endocrine treatment, medication adherence, quality of life
- İstanbul Üniversitesi Adresli: Evet
Özet
Introduction: Patients receiving long-term endocrine treatment (ET) for hormone receptor-positive breast cancer commonly use supportive-care and concomitant medicines, resulting in complex regimens with greater risks of drug-related problems (DRPs) and non-adherence. This study quantified DRPs per patient and assessed their management, potential drug–drug interactions, ET adherence, and within-patient quality-of-life (QoL) changes. Methods: This prospective, single-centre, single-arm pre–post study included 95 outpatients receiving ET. A clinical pharmacist reviewed medication regimens, classifying DRPs and interventions with Pharmaceutical Care Network Europe V9.0. Assessments included Micromedex screening for potential interactions, the 8-item Morisky Medication Adherence Scale for adherence, and the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23 for QoL at baseline and 2 months. Results: Overall, 287 DRPs were identified in 88 patients (92.6%; 3.02 ± 1.77 per patient): 15 (5.2%) involved ET, 118 (41.1%) supportive-care medicines, and 154 (53.7%) other concomitant medicines. Of 688 interventions, 686 (99.7%) were accepted, while 142 DRPs (49.5%) were completely resolved. Potential interactions were detected in 54 patients (56.8%); 54/110 (49.1%) were major. Low ET adherence was identified in 50/93 patients (53.8%). Among 85 patients with paired QoL data, global health/QoL and functional scores increased significantly. Higher DRP counts correlated with poorer QoL, whereas higher adherence correlated with lower symptom burden. Conclusions: DRPs extended beyond ET to patients’ complete medication regimens. Despite high intervention acceptance, complete resolution was less frequent. Controlled multicentre studies with longer follow-up are needed to evaluate the effects of clinical pharmacist-led care on DRP resolution, ET adherence, and QoL.